Items tagged with Hepatitis C
Report shows UNITAID’s approach vital to remove market barriers so millions can have equitable access to new treatments for infectious diseases
On 14-15 January 2016 in Vilnius, Lithuania, the European Union Joint Action on HIV and Co-infection Prevention and Harm Reduction (HA-REACT) held its first Partnership Forum to kick off activities. HA-REACT addresses existing gaps in the prevention of HIV and other co-infections, especially tuberculosis and viral hepatitis, among people who inject drugs. This is a three-year project which was launched in late 2015 with core funding from the European Union (EU), and is being implemented by 23 partners in 18 EU Member States. Twelve collaborating partners are contributing additional expertise, among them the European Centre for Disease Prevention and Control and the European Monitoring Centre for Drugs and Drug Addiction.
Groundbreaking pledge of United Nations agencies to end HIV, TB and viral hepatitis epidemics in Europe at high-level meeting on ending TB (post)
For the first time, 14 United Nations agencies have joined forces to end the epidemics of HIV, tuberculosis (TB) and viral hepatitis – Europe’s deadliest communicable diseases. The commitment was demonstrated with the launch of the first-ever United Nations Common Position on Ending HIV, TB and Viral Hepatitis through Intersectoral Collaboration in the WHO European Region.
Civil society reaction to the European Commission Staff Working Document on HIV/AIDS, TB and viral hepatitis (post)
Weak signals of political commitment
Call for expressions of interest: Systematic reviews on hepatitis B and hepatitis C co-infection with TB and MDR/RR-TB and the effects of co-administration of MDR/RR-TB and hepatitis C treatment (post)
The World Health Organization (WHO) Global TB Program has initiated a process to conduct systematic reviews for the collection and assessment of available evidence on the prevalence of viral hepatitis B and C among patients with TB and multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) and whether the concurrent treatment of drug-resistant TB and hepatitis C is safe and increases the likelihood of treatment success and reduces unfavourable treatment outcomes.
Medicines Patent Pool secures its first licence on promising long-acting technologies for malaria, TB, and hepatitis C (post)
Geneva, 21 September 2021 – The Medicines Patent Pool (MPP) today announced that it has signed a licence agreement with Tandem Nano Ltd (TNL), the University of Liverpool (UoL) start-up focused on the development of its proprietary long-acting nanosystems platform technology. The non-exclusive, worldwide licence covers the patents and expertise of promising long-acting injectable technologies (LAIs) that could be applied in three disease areas with a high prevalence in low- and middle-income countries (LMICs): malaria, tuberculosis (TB), and hepatitis C (HCV). The candidate LAIs, currently developed by the Centre of Excellence for Long-acting Therapeutics (CELT) based at UoL, could provide optimal doses of medicines for malaria chemoprophylaxis, TB prevention, and HCV cure. The research teams are designing medicines to be delivered through a single injection to achieve the desired effect on the pathogens over prolonged periods, suppressing the need for daily oral pills, among many other advantages at the individual and the community levels.
People with hepatitis C, either treated or untreated, had an increased risk for developing active tuberculosis, according to data published in Clinical Infectious Diseases.
Standards of care: HIV, VH, and TB - good practices and ensuring prevention & care for people on the move (post)
The EU Health Policy Platform Thematic Network on HIV, TB and viral hepatitis will host a webinar on 16 February 2023 providing an overview of key standards of care for people living with or most affected by HIV/AIDS, viral hepatitis (VH), TB (especially drug-resistant) and gaps. It will also look at ways to ensure continued prevention and care for displaced and mobile people and other migrant populations.
Standards of care: HIV, VH, and TB - good practices and ensuring prevention & care for people on the move: Webinar materials now available online (post)
The EU Health Policy Platform Thematic Network on HIV, TB and viral hepatitis (VH) hosted a webinar on 16 February 2023 providing an overview of key standards of care for people living with or most affected by HIV/AIDS, VH, TB (especially drug-resistant) and gaps. It also looked at ways to ensure continued prevention and care for displaced and mobile people and other migrant populations.
Public call for experts with experience in the co-administration of treatment for drug-resistant TB and hepatitis C (post)
A recent systematic review, commissioned by the World Health Organization (WHO), demonstrated that the prevalence of chronic hepatitis C virus (HCV) infection is high among patients with TB. Published evidence on the safety and effectiveness of co-administering treatment for rifampicin-resistant TB and HCV co-infection is extremely scarce and insufficient as a basis to develop global policy recommendations on this intervention.
Page 1 of 3 · Total posts: 01 2 Last→